Neural Therapeutics (FRA:M6B) 3-1 Month Momentum %: -26.09% (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics 3-1 Month Momentum %?

Neural Therapeutics FRA:M6B 3-1 Month Momentum % is -26.09% as of Sep. 11, 2026. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, Neural Therapeutics ranks worse than 72254.26% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-11), Neural Therapeutics's 3-1 Month Momentum % is -26.09%.

The industry rank for Neural Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

FRA:M6B's 3-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: 2.12 vs FRA:M6B: -26.09

Neural Therapeutics  (FRA:M6B) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Neural Therapeutics 3-1 Month Momentum % Related Terms

FRA:M6B vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Neural Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neural Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neural Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Neural Therapeutics's 3-1 Month Momentum % falls into.


Neural Therapeutics  (FRA:M6B) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -26.09% mean?
Neural Therapeutics (FRA:M6B) has a 3-1 Month Momentum % of -26.09% as of Sep. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #999999 out of 1384 companies in the Biotechnology industry.
Is Neural Therapeutics' 3-1 Month Momentum % too high?
Neural Therapeutics' current 3-1 Month Momentum % is -26.09%. Based on the distribution chart, Neural Therapeutics ranks #999999 out of 1384 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neural Therapeutics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #999999 out of 1384 companies for 3-1 Month Momentum %. This places Neural Therapeutics in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 2.12, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Neural Therapeutics and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neural Therapeutics's current 3-1 Month Momentum % is -26.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current 3-1 Month Momentum % of -26.09%. The current 3-1 Month Momentum % is -26.09%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current 3-1 Month Momentum % is -26.09% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges NURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.